Contact
Search
Contact
Search
Changing Lives. NOW
Investing in Health Care
Changing Lives. NOW
Treating Heart Failure
Changing Lives. NOW
Detecting Breast Cancer
Changing Lives. NOW
Detecting Breast Cancer
Changing Lives. NOW
Managing Chronic Pain
Changing Lives. NOW
Preventing Blindness
Changing Lives. NOW
Preventing Blindness
Changing Lives. NOW
Managing Chronic Pain
Changing Lives. NOW
Detecting Breast Cancer
Changing Lives. NOW
Managing Chronic Pain
Changing Lives. NOW
Managing Chronic Pain
Changing Lives. NOW
Preventing Blindness
Changing Lives. NOW
Preventing Blindness
Previous slide
Next slide

How we change lives

ABOUT

US

Investing in Healthcare

Investing in the resilient Health Care sector

Horizon 3 is building a portfolio we expect to deliver an IRR of 20% per annum over a 5 year timeframe. *

Investing in healthcare products that have global growth potential – medical devices, drugs, digital health and diagnostics.

* returns are not guaranteed

Backing companies with runs on the board

Growth stage healthcare companies with runs on the board – typically already have achieved clinical validation and are revenue generating.

World Class CIO

Led by one of Australia’s Leading Healthcare investors, CIO Matt McNamara, Molecular biologist

Previous funds delivered top quartile returns and backed 3 unicorns.

Horizon 3 is Matt’s 5th fund over the past 20+ years.

Investment Portfolio

We invest in the long term by contributing capital, business excellence, deep commercialisation partnerships and unparalleled health science expertise.

From bright thinking to better health outcomes, and ultimately returns for our investors.

INVEST

PORTFOLIO

LumiThera

Developing Photobiomodulation Treatments for Ocular Diseases and Disorders
Visit Website

Cardiac Dimensions

Caridiac Dimensions is on a mission to bring more success to the treatment of heart failure patients.
Visit Website

Canary Health

Canary creates a voice for medical implants by allowing them to generate and share data.
Visit Website

EBR Systems

The WiSE CRT System was developed to address the persistent limitations of current CRT systems and to provide a more customized, patient-specific solution.
Visit Website

Avecho

Avecho’s TPM® (tocopheryl phosphate mixture) is a world-first drug delivery platform with a proprietary blend of two forms of tocopheryl phosphate, an enhanced form of Vitamin E, with proven clinical benefits.
Visit Website

Neuren

Neuren is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options.
Visit Website
See our investment portfolio

OUR TEAM

We are a powerful team made up of seasoned entrepreneurs, life science specialists and experienced investors who are experts at finding great ideas in which to invest. Our efforts are focused on selecting talented life sciences teams and companies with huge potential.

Matt McNamara Chief Investment Officer & Board Director
Michael Yassa Investment Associate
Bev Thomas Senior Investment Professional & Investment Committee Member
Paul Field Life Sciences Business Development Exec & Investment Committee Member
Dr Qibing Mei Pharmacologist & Investment Committee Member
Scott Power Investment Analyst & Investment Committee Member
Assoc Prof Tam Nguyen Non-Executive Director and Deputy Director of Research

Mike Sullivan
Banking and Capital Markets Executive & Board Executive Chairman

Jian Sun
Entrepreneur and founder of HK Biotechnology & Board Director

Robin Chambers AO
Corporate Lawyer and Advisor & Board Director

Glenn Cross
Senior Corporate Advisor & Board Director

Claire Newstead-Sinclair
Company Secretary

OUR

TEAM
See our Team

Contact

Email your message to H3 Healthcare